REG - SkinBioTherapeutics - Notice of Results

SkinbiotherapeuticsAnnouncement

29/11/2024 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241129:nRSc2136Oa&default-theme=true

RNS Number : 2136O  SkinBioTherapeutics PLC  29 November 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Group")

 

Notice of Full Year results and Investor Meet Company presentation

29 November 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that the Group's full year results for the
year to 30 June 2024 will be released on Wednesday 4 December 2024.

The results will be available via the London Stock Exchange's Regulatory News
Service (RNS) and on the Investor Relations section of the Group's website
HERE
(https://www.skinbiotherapeutics.com/investor-relations/company-announcements/)
.

Stuart Ashman, CEO and Manprit Randhawa, CFO will provide a live presentation
via the Investor Meet Company platform at 10.00am GMT on Tuesday 10 December
2024.

The presentation is open to all existing and potential SkinBioTherapeutics
shareholders. Questions can be submitted pre-event via the Investor Meet
Company dashboard
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc) up
until 9 December 2024, 09.00am GMT, or at any time during the live
presentation.

Investors can sign up to Investor Meet Company for free via this link
(http://www.investormeetcompany.com/companies/skinbiotherapeutics-plc) .
Investors who already follow SkinBioTherapeutics plc on the Investor Meet
Company platform will automatically be invited.

-Ends-

For more information please contact:

 

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements to modulate the immune system by harnessing the gut-skin
axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and
the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to
address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBGBDBCUDDGSC